arrow
L

Laura M. Amendola

national institutes of health (nih) - usa
H指数:37
被引数:6,810

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ACMG SF v3.3 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG)

ACMG SF v3.3 临床全外显子和全基因组测序次级发现报告清单:美国医学遗传学与基因组学学院(ACMG)的政策声明

2025-06-230
PRE
Expanded Newborn Screening Using Genome Sequencing for Early Actionable Conditions

使用基因组测序扩展新生儿筛查早期可行条件

2025-01-213
PRE
LETTER TO THE EDITOR Response to Stern

致编辑的信对斯特恩的回应

2024-02-010
OAAI
An accessible, relational, inclusive, and actionable (ARIA) model of genetic counseling compared with usual care: Results of a randomized controlled trial
2022-11-017
PRE
ORCA, a values-based decision aid for selecting additional findings from genomic sequencing in adults: Efficacy results from a randomized trial
2022-08-015
OAAI
Lessons learned and recommendations for data coordination in collaborative research: The CSER consortium experience
2022-07-016
OAAI
Laboratory-related outcomes from integrating an accessible delivery model for hereditary cancer risk assessment and genetic testing in populations with barriers to access
2022-06-018
OA
Variants in PRKAR1B cause a neurodevelopmental disorder with autism spectrum disorder, apraxia, and insensitivity to pain

PRKAR1B的变异导致自闭症谱系障碍,失用症和对疼痛不敏感的神经发育障碍

2021-08-0115
OAAI
ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG) (Aug, 2021, 10.1038/s41436-021-01172-3)
2021-08-0113
PREAI